Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05762705 · ClinicalTrials.gov registry record · NA

A Mobile Gaming App to Improve Adherence to PrEP

A NA study of HIV/AIDS and Medication Adherence, sponsored by Rhode Island Hospital.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
3
Study locations

NCT05762705: Recruiting NA study of HIV/AIDS and Medication Adherence, sponsored by Rhode Island Hospital.

NCT05762705 is a NA study of HIV/AIDS and Medication Adherence that is actively recruiting participants, run by Rhode Island Hospital. The registered enrollment target is 200 participants, below the 33,177-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05762705, a NA study of HIV/AIDS and Medication Adherence, is actively recruiting participants, sponsored by Rhode Island Hospital.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
3
Study locations

Study Summary

In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthcare workers, clinic administrators, and patients taking PrEP) to inform intervention delivery. Data from the formative interviews will also be used to make necessary adaptations to the game and assess acceptability for diverse populations and clinics. Viral Combat will then be further tested with 200 participants ages 15-34 years, receiving PrEP care at clinical sites in the South (n=100 Jackson, MS) and New England (n=100, Providence, RI; Boston, MA) in a multisite Hybrid Type 1 effectiveness-implementation randomized controlled trial (RCT). This trial will test the efficacy of the intervention compared to a control condition (a non-PrEP related game) on biological and behavioral measures. At the end of the trial, a summative evaluation of the implementation context using the i-PARIHS framework will occur. These interviews with study participants and clinic staff will inform future implementation and dissemination of Viral Combat.

Primary Outcome

Tenofovir (TFV) concentration in blood from either venipuncture or dried blood spot labs immediately post-intervention (at 24 weeks follow-up).

Interventions

  • BEHAVIORAL Multilevel Gaming Adherence Intervention
  • BEHAVIORAL Treatment as Usual +

Study Locations (3)

Massachusetts

  • Boston Medical Center - Boston

Mississippi

  • University of Mississippi Medical Center - Jackson

Rhode Island

  • Lifespan (The Miriam Hospital and Rhode Island Hospital) - Providence

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-06-21
Est. Completion 2027-03-03
Phase NA
Rhode Island Hospital

130 total trials

What NCT05762705 shows while recruiting

NCT05762705 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 33,177-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with HIV/AIDS appearing as the primary indexed condition, and to 2 interventions - of which Multilevel Gaming Adherence Intervention is the first listed.

NCT05762705 reports a single indexed study location in Massachusetts, Mississippi, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT05762705 about?

NCT05762705 is a clinical study titled "A Mobile Gaming App to Improve Adherence to PrEP". In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthc...

What is the current status of trial NCT05762705?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-06-21. Estimated completion is 2027-03-03.

What conditions does trial NCT05762705 study?

This clinical trial studies the following conditions: HIV/AIDS, Medication Adherence.

What interventions are being tested in trial NCT05762705?

The interventions under investigation include: Multilevel Gaming Adherence Intervention (BEHAVIORAL), Treatment as Usual + (BEHAVIORAL).

Who is sponsoring clinical trial NCT05762705?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05762705 being conducted?

This trial has 3 study locations across Massachusetts, Mississippi, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05762705's enrollment target sits among peer trials

200 25th of 61 higher than 36 of 61 other HIV/AIDS trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05762705, the US trial registry maintained by the National Library of Medicine. NCT05762705 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.